476 related articles for article (PubMed ID: 30692993)
1. Combining Radiotherapy With Anti-angiogenic Therapy and Immunotherapy; A Therapeutic Triad for Cancer?
Goedegebuure RSA; de Klerk LK; Bass AJ; Derks S; Thijssen VLJL
Front Immunol; 2018; 9():3107. PubMed ID: 30692993
[TBL] [Abstract][Full Text] [Related]
2. Vascular Targeting to Increase the Efficiency of Immune Checkpoint Blockade in Cancer.
Georganaki M; van Hooren L; Dimberg A
Front Immunol; 2018; 9():3081. PubMed ID: 30627131
[TBL] [Abstract][Full Text] [Related]
3. Therapeutic Targeting of the Colorectal Tumor Stroma.
Fridman WH; Miller I; Sautès-Fridman C; Byrne AT
Gastroenterology; 2020 Jan; 158(2):303-321. PubMed ID: 31622621
[TBL] [Abstract][Full Text] [Related]
4. The Reciprocity between Radiotherapy and Cancer Immunotherapy.
Wang Y; Liu ZG; Yuan H; Deng W; Li J; Huang Y; Kim BYS; Story MD; Jiang W
Clin Cancer Res; 2019 Mar; 25(6):1709-1717. PubMed ID: 30413527
[TBL] [Abstract][Full Text] [Related]
5. Optimized antiangiogenic reprogramming of the tumor microenvironment potentiates CD40 immunotherapy.
Kashyap AS; Schmittnaegel M; Rigamonti N; Pais-Ferreira D; Mueller P; Buchi M; Ooi CH; Kreuzaler M; Hirschmann P; Guichard A; Rieder N; Bill R; Herting F; Kienast Y; Dirnhofer S; Klein C; Hoves S; Ries CH; Corse E; De Palma M; Zippelius A
Proc Natl Acad Sci U S A; 2020 Jan; 117(1):541-551. PubMed ID: 31889004
[TBL] [Abstract][Full Text] [Related]
6. Current status and limitations of immunotherapy for breast cancer.
Tokumaru Y; Joyce D; Takabe K
Surgery; 2020 Mar; 167(3):628-630. PubMed ID: 31623855
[No Abstract] [Full Text] [Related]
7. Priming the tumor immune microenvironment with chemo(radio)therapy: A systematic review across tumor types.
van den Ende T; van den Boorn HG; Hoonhout NM; van Etten-Jamaludin FS; Meijer SL; Derks S; de Gruijl TD; Bijlsma MF; van Oijen MGH; van Laarhoven HWM
Biochim Biophys Acta Rev Cancer; 2020 Aug; 1874(1):188386. PubMed ID: 32540465
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer immunotherapy: where are we and where are we going?
De Velasco MA; Uemura H
Curr Opin Urol; 2018 Jan; 28(1):15-24. PubMed ID: 29095729
[TBL] [Abstract][Full Text] [Related]
9. Immune resilience in response to cancer therapy.
Gicobi JK; Barham W; Dong H
Cancer Immunol Immunother; 2020 Nov; 69(11):2165-2167. PubMed ID: 33011909
[No Abstract] [Full Text] [Related]
10. Combination immunotherapy in metastatic renal cell carcinoma. Are we leaving something back?
Di Nunno V; Gatto L; Fragomeno B; Cubelli M; Nobili E; Romano I; Santoni M; Pisconti S; Montironi R; Massari F
Future Oncol; 2018 Dec; 14(29):2997-2999. PubMed ID: 30411632
[No Abstract] [Full Text] [Related]
11. Expression of costimulatory and inhibitory receptors in FoxP3
Toker A; Ohashi PS
Adv Cancer Res; 2019; 144():193-261. PubMed ID: 31349899
[TBL] [Abstract][Full Text] [Related]
12. Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment.
Darragh LB; Oweida AJ; Karam SD
Front Immunol; 2018; 9():3154. PubMed ID: 30766539
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy and Combination Strategies in Pancreatic Cancer: Current Status and Emerging Trends.
Cheung PF; Lutz M; Siveke JT
Oncol Res Treat; 2018; 41(5):286-290. PubMed ID: 29705789
[TBL] [Abstract][Full Text] [Related]
14. Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment.
Hameed S; Bhattarai P; Dai Z
Sci China Life Sci; 2018 Apr; 61(4):380-391. PubMed ID: 29607461
[TBL] [Abstract][Full Text] [Related]
15. Reprogramming the Tumor Microenvironment to Improve Immunotherapy: Emerging Strategies and Combination Therapies.
Datta M; Coussens LM; Nishikawa H; Hodi FS; Jain RK
Am Soc Clin Oncol Educ Book; 2019 Jan; 39():165-174. PubMed ID: 31099649
[TBL] [Abstract][Full Text] [Related]
16. Clinical development of immunotherapy for prostate cancer.
Noguchi M; Koga N; Igawa T; Itoh K
Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
[TBL] [Abstract][Full Text] [Related]
17. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future.
Hamming LC; Slotman BJ; Verheul HMW; Thijssen VL
Angiogenesis; 2017 May; 20(2):217-232. PubMed ID: 28364160
[TBL] [Abstract][Full Text] [Related]
18. Combining angiogenesis inhibition and radiotherapy: a double-edged sword.
Kleibeuker EA; Griffioen AW; Verheul HM; Slotman BJ; Thijssen VL
Drug Resist Updat; 2012 Jun; 15(3):173-82. PubMed ID: 22561672
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer.
Lazăr DC; Avram MF; Romoșan I; Cornianu M; Tăban S; Goldiș A
World J Gastroenterol; 2018 Aug; 24(32):3583-3616. PubMed ID: 30166856
[TBL] [Abstract][Full Text] [Related]
20. Anti-Angiogenics: Their Value in Colorectal Cancer Therapy.
Seeber A; Gunsilius E; Gastl G; Pircher A
Oncol Res Treat; 2018; 41(4):188-193. PubMed ID: 29562227
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]